Evaluation of the effectiveness of Milrinone in the treatment of patients with aluminum phosphide poisoning .

Evaluation of the effectiveness of Milrinone in the treatment of patients with aluminum phosphide poisoning.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251008067554N1

Enrollment

Registered

2025-11-15

Start date

2022-09-01

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aluminum Phosphide Poisoning. -

Interventions

Intervention 1: Intervention group: Treated with milrinone in addition to conventional treatments for aluminum phosphide poisoning (according to the Ministry of Health protocol). Intervention 2: Contr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients had a documented history of aluminum phosphide consumption. Onset of symptoms of cardiogenic shock within the first 6 hours of hospitalization

Exclusion criteria

Exclusion criteria: Absence of any clinical or paraclinical signs or symptoms of aluminum phosphide poisoning within the first 6 hours of hospital admission Sensitivity to the drugs being studied

Design outcomes

Primary

Measure	Time frame
Systolic blood pressure. Timepoint: Every hour after admission to the hospital until 48 hours after the start of treatment. Method of measurement: Patients' systolic blood pressure is automatically monitored by a vital signs monitor.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hossein Poorrajabi Firoozabad

Tehran University of Medical Sciences

hpourrajabi1982@gmail.com+98 35 3234 5508

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026